Parkinson Disease Clinical Trials in Kansas City, Kansas

6 studies are recruiting for parkinson disease in Kansas City, Kansas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

   The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic p…

   Stage

   Phase 2

   Ages

   40 to 80

   Site

   University of Kansas Medical Center, Kansas City, Kansas

   Locations

   72 in total

   Run by

   Neuron23 Inc.

   See if you can join NCT06680830 on ClinicalTrials.gov

2. A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

   This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa treatment, compared with a placebo. The study will last about 14 weeks. P…

   Stage

   Phase 2

   Ages

   30 to 80

   Site

   The University of Kansas (KU) (Site #216), Kansas City, Kansas

   Locations

   30 in total

   Run by

   Appello Pharmaceuticals, Inc.

   See if you can join NCT07432958 on ClinicalTrials.gov

3. A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

   A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease. The study will consist of a 48-week double-blind treatment phase followed by a 48-week open-label phase.

   Stage

   Phase 2

   Ages

   40 to 80

   Site

   Site-029, Kansas City, Kansas

   Locations

   25 in total

   Run by

   Biohaven Therapeutics Ltd.

   See if you can join NCT06976268 on ClinicalTrials.gov

4. PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort

   The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest…

   Stage

   Not phased

   Ages

   30 and older

   Site

   University of Kansas Medical Center, Kansas City, Kansas

   Locations

   50 in total

   Run by

   Michael J. Fox Foundation for Parkinson's Research

   See if you can join NCT04477785 on ClinicalTrials.gov

5. Abbott DBS Post-Market Study of Outcomes for Indications Over Time

   The purpose of this international study is to evaluate long-term safety and effectiveness of Abbott deep brain stimulation (DBS) systems for all indications, including Parkinson's disease, essential tremor or other disabling tremor and dystonia.

   Stage

   Not phased

   Ages

   Any age

   Site

   Kansas University Medical Center, Kansas City, Kansas

   Locations

   48 in total

   Run by

   Abbott Medical Devices

   See if you can join NCT04071847 on ClinicalTrials.gov

6. A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

   The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).

   Stage

   Phase 4

   Ages

   18 and older

   Site

   University of Kansas Medical Center, Kansas City, Kansas

   Locations

   27 in total

   Run by

   Impax Laboratories, LLC

   See if you can join NCT06765668 on ClinicalTrials.gov